Search research articles
Contact Us
Filters
Showing results (131-140 of 316) with videos related to
Page
of 32
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1995
Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation
J G Villablanca, A A Khan, V I Avramis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 15, 2019
Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma
Vanessa P Tolbert, Christopher C Dvorak, Carla Golden, et al.
Cancer Research
|
October 1, 2024
Editor's Note: Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma
Louis Chesler, Chris Schlieve, David D Goldenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2005
Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study
Mary Lou Schmidt, Ashutosh Lal, Robert C Seeger, et al.
Cancer
|
July 2, 2003
Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients
Katherine K Matthay, Hervé Brisse, Dominique Couanet, et al.
British Journal of Cancer
|
January 21, 2015
Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma
S G DuBois, S Allen, M Bent, et al.
Cancer Medicine
|
December 14, 2020
Association of image-defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma
William C Temple, Kieuhoa T Vo, Katherine K Matthay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2004
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma
Steven G DuBois, Julia Messina, John M Maris, et al.
Medical and Pediatric Oncology
|
December 7, 2000
Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors
H Goto, N Keshelava, K K Matthay, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 7, 2001
Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG
K K Matthay, C Panina, J Huberty, et al.
Page
of 32
Search research articles
Search
Showing results (131-140 of 316) with videos related to
Sort By:
Page
of 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1995
Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation
J G Villablanca, A A Khan, V I Avramis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 15, 2019
Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma
Vanessa P Tolbert, Christopher C Dvorak, Carla Golden, et al.
Cancer Research
|
October 1, 2024
Editor's Note: Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma
Louis Chesler, Chris Schlieve, David D Goldenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2005
Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study
Mary Lou Schmidt, Ashutosh Lal, Robert C Seeger, et al.
Cancer
|
July 2, 2003
Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients
Katherine K Matthay, Hervé Brisse, Dominique Couanet, et al.
British Journal of Cancer
|
January 21, 2015
Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma
S G DuBois, S Allen, M Bent, et al.
Cancer Medicine
|
December 14, 2020
Association of image-defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma
William C Temple, Kieuhoa T Vo, Katherine K Matthay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2004
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma
Steven G DuBois, Julia Messina, John M Maris, et al.
Medical and Pediatric Oncology
|
December 7, 2000
Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors
H Goto, N Keshelava, K K Matthay, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 7, 2001
Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG
K K Matthay, C Panina, J Huberty, et al.
Page
of 32